The human placenta, a transient but vital organ, governs fetal development and maternal-fetal interactions, yet its study has been stymied by ethical and accessibility constraints. Stem cell biology has now revolutionized the capacity to model human placental development, in particular with the derivation of human trophoblast stem cells (hTSCs) and organoids. Classically, hTSCs have been derived from pluripotent stem cells (PSCs) such as ESCs or iPSCs, which, under defined culture signals, can be directed into trophoblast lineages by manipulation of master regulatory pathways including GATA3, TFAP2C, and BMP4. However, a quantum leap has come with pluripotency-independent reprogramming, where somatic cells (e.g., fibroblasts) are reprogrammed directly into hTSCs. By bypassing the pluripotent stage with these specific transcription factors and trophoblast-supporting conditions, this approach enhances the efficiency, safety, and disease modeling potential of hTSC derivation. An important advance underlying these improvements is the mapping of a global reprogramming roadmap. Multi-omic and lineage-tracing experiments have mapped the stepwise transcriptional and epigenetic conversions of fibroblasts to hTSCs, including sequential chromatin reconfiguration, trophoblast gene network activation, and repression of somatic signatures. These results identify major regulatory bottlenecks and intermediate states, improving reprogramming fidelity. The derivation of stem-cell-based trophoblast organoids now enables complex modeling of placental architecture, function, and disease susceptibility in vitro. These organoids accurately recapitulate placental barrier functions and immunological features, allowing for examinations of maternal-fetal health, pregnancy disorders, and placental infection response to viruses like cytomegalovirus and SARS-CoV-2. Looking ahead, the integration of reprogramming and organoid technologies will propel patient-specific and tailor-made models for personalized diagnostics, drug screening, and mechanism studies. As we unravel the molecular ballet of trophoblast induction, such discoveries have the potential to bridge basic translational gaps in reproductive biology and maternal-fetal medicine.